Search research articles
Contact Us
Filters
Showing results (21-30 of 65) with videos related to
Page
of 7
Sort By:
Journal of Clinical and Diagnostic Research : JCDR
|
October 11, 2014
Clindamycin 1% Nano-emulsion Gel Formulation for the Treatment of Acne Vulgaris: Results of a Randomized, Active Controlled, Multicentre, Phase IV Clinical Trial
Bhavik Bhavsar, Bimal Choksi, Jayesh Sanmukhani, et al.
The Oncologist
|
November 6, 2024
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma
Karam Khaddour, Rizwan Haq, Elizabeth I Buchbinder, et al.
Molecular Cancer Therapeutics
|
June 2, 2026
Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605
Kristýna Kotýnková, Sawyer Andersen, Daniel Denney, et al.
Pigment Cell & Melanoma Research
|
June 19, 2025
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response
Ethan Trim, Anita Giobbie-Hurder, Tamara A Sussman, et al.
Dermatology and Therapy
|
August 28, 2021
Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
Srinivas Sidgiddi, Syed Mujtaba Hussain Naqvi, Manjunath Shenoy, et al.
The Journal of Clinical Investigation
|
May 17, 2024
Somatic structural variants drive distinct modes of oncogenesis in melanoma
Jake R Conway, Riaz Gillani, Jett Crowdis, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2019
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
Girish S Naik, Sushrut S Waikar, Alistair E W Johnson, et al.
Expert Review of Clinical Pharmacology
|
September 4, 2024
Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement
Kabir Sardana, C R Srinivasan, Mukesh Girdhar, et al.
Cancer Immunology, Immunotherapy : CII
|
January 22, 2021
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
Kevin Tyan, Joanna Baginska, Martha Brainard, et al.
Cancer Research Communications
|
April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Elizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 65) with videos related to
Sort By:
Page
of 7
Journal of Clinical and Diagnostic Research : JCDR
|
October 11, 2014
Clindamycin 1% Nano-emulsion Gel Formulation for the Treatment of Acne Vulgaris: Results of a Randomized, Active Controlled, Multicentre, Phase IV Clinical Trial
Bhavik Bhavsar, Bimal Choksi, Jayesh Sanmukhani, et al.
The Oncologist
|
November 6, 2024
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma
Karam Khaddour, Rizwan Haq, Elizabeth I Buchbinder, et al.
Molecular Cancer Therapeutics
|
June 2, 2026
Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605
Kristýna Kotýnková, Sawyer Andersen, Daniel Denney, et al.
Pigment Cell & Melanoma Research
|
June 19, 2025
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response
Ethan Trim, Anita Giobbie-Hurder, Tamara A Sussman, et al.
Dermatology and Therapy
|
August 28, 2021
Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
Srinivas Sidgiddi, Syed Mujtaba Hussain Naqvi, Manjunath Shenoy, et al.
The Journal of Clinical Investigation
|
May 17, 2024
Somatic structural variants drive distinct modes of oncogenesis in melanoma
Jake R Conway, Riaz Gillani, Jett Crowdis, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2019
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
Girish S Naik, Sushrut S Waikar, Alistair E W Johnson, et al.
Expert Review of Clinical Pharmacology
|
September 4, 2024
Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement
Kabir Sardana, C R Srinivasan, Mukesh Girdhar, et al.
Cancer Immunology, Immunotherapy : CII
|
January 22, 2021
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
Kevin Tyan, Joanna Baginska, Martha Brainard, et al.
Cancer Research Communications
|
April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Elizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.
Page
of 7